secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vistagen Therapeutics, Inc. (VTGN)
CIK:        0001411685
Form:       8-K
Filed at:   2025-01-13T23:59:59+00:00
Accession:  0001411685-25-000004
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vistagen enrolls first subject in fasedienol repeat dose study for social anxiety disorder
--------------------------------------------------------------------------------

- Phase 2 exploratory trial evaluating repeat dose of fasedienol (3.2 mcg) in adults with SAD during a public speaking challenge.
- Three arms: fasedienol+fasedienol (total 6.4 mcg), fasedienol+placebo (3.2 mcg), placebo+placebo; second dose 10 min after initial.
- Study design mirrors ongoing PALISADE Phase 3 program including open-label extension.
- CEO notes no FDA-approved acute treatment option exists for SAD despite high prevalence.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1411685/000141168525000004/0001411685-25-000004-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1411685/000141168525000004/vtgn-20250110.htm
  HTML page:      https://secwatch.observer/filing/0001411685-25-000004

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer